What Carolina Molecular does

Carolina Molecular is a privately held molecular testing laboratory headquartered in Morrisville, North Carolina (Research Triangle Park), that delivers CAP/CLIA-certified and NYS-registered clinical testing alongside research-use-only sequencing services for pharmaceutical, biotechnology, contract research organization (CRO), and contract development and manufacturing organization (CDMO) clients. The lab operates a multiomic platform spanning next-generation sequencing (Illumina NovaSeq X Plus, NextSeq, MiSeq, and Element AVITI), qPCR, Sanger sequencing, Luminex multiplex immunoassays, GeoMx Digital Spatial Profiling, single-cell RNA sequencing, and integrated bioinformatics, with USDA APHIS permitting extending services into agricultural genomics and food safety. The company reports over 50 validated molecular assays, a 25-year operational pedigree traced through Gentris, Cancer Genetics, and Flagship Biosciences, and more than 200 active clients.

The business runs on a project-based professional services model with pay-as-you-go unit pricing on its NGS Foundry offering, quote-based clinical services, and transparent per-run and per-lane pricing for select sequencing platforms. Go-to-market combines direct enterprise field sales, technology partner referrals from certified platform providers (CS Genetics, Pixelgen, Alamar, Element, GeoMx/Nanostring, Illumina), and a self-serve listing on the Scientist.com marketplace. Distribution is anchored at a single RTP laboratory with free local courier pickup, while the September 2025 partnership with Astoriom extends integrated molecular testing and ICH-compliant biospecimen storage across US, EU, and UK markets. Carolina Molecular is founder-owned and led by Trent Carrier (CEO/President) and John Corliss (Co-Founder), with no disclosed institutional investors beyond a $1.125M funding round in November 2025.

Name

Carolina Molecular

Legal name

Carolina Molecular Inc.

Website

https://carolinamolecular.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Short description

Carolina Molecular is a CAP/CLIA-certified molecular testing laboratory in Research Triangle Park, NC, providing NGS, qPCR, spatial biology, and bioinformatics services to pharmaceutical, biotech, and CRO clients across US, EU, and UK markets.

Ownership category

akta.pro rank

Product category

Molecular Diagnostic and Genomics Testing Services

NAICS

Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

akta.pro secondary industries

Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Clinical Research & Trial Central Laboratories (HLAFAMAL)

Keywords

• Molecular testing services
• Next-generation sequencing
• Clinical genomics laboratory
• Bioinformatics analysis
• Multiomic profiling services

Headquarters

HQ city

Morrisville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Molecular Testing Services: CAP/CLIA-certified and NYS-registered molecular testing services for clinical trials, including oncology (solid tumor, blood cancer, MRD/liquid biopsy), infectious disease, and immunology (HLA, immune profiling, spatial expression, proteomic profiling, single-cell). Revenue generated through project-based fees per assay or sample.
2. NGS Foundry / RUO Sequencing: Research Use Only (RUO) sequencing services with pre-purchased capacity units, transparent per-run and per-lane pricing, primary analytics included. Targets technology partners, core labs, and service labs seeking flexible, rapid sequencing without instrument investment.
3. Agricultural Genomics & Food Safety Testing: Whole genome sequencing and bioinformatics for agricultural research (soil health, crop research, GMO/transgenic research) and food safety (strain-level pathogen identification, contamination investigation). Project-based fees for diverse sample types including probiotics, protein powders, and industrial materials.
4. Bioinformatic Analysis Services: Custom bioinformatics and multiomic data analysis services including pipeline development, variant annotation, clinical reporting, and integrated multiomic insights. Provided as standalone consulting or bundled with testing services.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Carolina Molecular operates a CAP/CLIA-certified, NYS-registered molecular testing laboratory delivering NGS, qPCR, Sanger, multiplex immunoassay, and digital spatial profiling services for clinical and research applications. Its core offerings are organized into an NGS Foundry for flexible RUO sequencing, Clinical Services for regulated molecular testing, Bioinformatics for primary-to-tertiary multiomic analysis, and integrated Proteomic, Spatial, and Multiomic Services, with a complementary Agricultural Genomics and Food Safety practice.

Product overview

Carolina Molecular is a molecular testing services laboratory operating as a platform-plus-partnerships model. The core offerings include the NGS Foundry for research-use sequencing, Clinical Services for CAP/CLIA-certified clinical testing, Bioinformatics for multiomic data analysis, and Proteomic/Spatial/Multiomic Services for integrated protein and transcriptomic profiling. These services are enhanced through technology partnerships including Element Biosciences AVITI, CS Genetics SimpleCell, Pixelgen Proxiome, Alamar Biosciences ARGO, PhenoVista imaging, and Flagship Biosciences spatial biology. The company also offers specialized Agricultural Genomics and Food Safety Solutions. All services are supported by bioinformatic analysis capabilities and quality management systems spanning research use only through clinical-grade testing.

Differentiator

Problem solved

Functional benefit

Products and services

• NGS Foundry Flexible next-generation sequencing service for technology partners, core labs, and service labs providing transparent per-run and per-lane pricing with pre-purchased capacity units, online scheduling, primary analytics included, and approximately 1-week sample-to-data turnaround. Supports WGS, WES, single-cell, spatial, and RNA sequencing across Illumina and Element AVITI platforms.
• Clinical Services CAP/CLIA-certified and NYS-registered molecular testing for clinical trial programs covering oncology (solid tumor, blood cancer, MRD, liquid biopsy, methylation), infectious disease (de novo ID, metagenomics, qPCR, genotyping), and immunology (HLA, immune profiling, spatial expression, proteomic profiling, single-cell). Designed for pharma, biotech, and CRO sponsors requiring regulated clinical-grade workflows.
• Bioinformatics Multiomic data analysis services spanning experimental design, pipeline development and validation, variant annotation, clinical reporting, biomarker discovery, and integrated multiomic insights for oncology, metagenomics, spatial biology, and translational research. Available standalone or bundled with testing services.
• Proteomic, Spatial, and Multiomic Services (Discovery Omics) Integrated suite combining GeoMx Digital Spatial Profiler, Luminex multiplex immunoassays, CS Genetics SimpleCell scRNA-Seq, Pixelgen Proxiome Kit protein interactomics, and cell painting for biomarker discovery and therapeutic target validation across immunology, immuno-oncology, cell therapy, and neuroscience applications.
• Agricultural Genomics and Food Safety Solutions Whole-genome sequencing and bioinformatics for soil health, crop research, GMO/transgenic characterization, strain-level pathogen identification, and contamination investigation of probiotics, protein powders, and industrial materials, conducted in a USDA APHIS-permitted facility.

Quantifiable outcome

• Sample-to-data in approximately 1 week
• +4 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature8 records

Partnerships

Ten partnerships are on record, tiered minor and core.

• Sword BiominorStrategic or Co-development Partner · 1 May 2026Carolina Molecular works with Sword Bio (and its CSO Jim McNally) as a collaboration partner in gene therapy and biologics bioanalytical development. The companies discuss CRO-industry trends, multi-omics integration, and emerging therapeutic modalities, with Sword Bio providing senior scientific engagement throughout the program lifecycle.
• Alamar BiosciencescoreTechnology or Integration · 8 April 2026Carolina Molecular was named a certified sequencing service provider by Alamar Biosciences, accepting ARGO HT libraries from Alamar's growing installed base. This expands Carolina Molecular's multiomic capabilities by bridging ultra-sensitive NULISA protein detection with industry-leading NGS accuracy for complex discovery and translational studies.
• Element BiosciencescoreTechnology or Integration · 19 March 2026Carolina Molecular is the only certified AVITI service provider in the Southeast, having integrated Element Biosciences' AVITI System into its NGS Foundry. The AVITI platform's proprietary avidity chemistry delivers high data quality and is processed within Carolina Molecular's CAP/CLIA accredited Quality Management System.
• Pixelgen TechnologiescoreTechnology or Integration · 12 November 2025Carolina Molecular became the first certified US service provider for Pixelgen's Proxiome Kit (Proximity Network Assay), expanding access to 3D protein interactomics for US researchers. The partnership leverages Carolina Molecular's NGS Foundry and bioinformatics expertise to deliver high-quality protein-protein interaction data for immuno-oncology, cell therapy, auto-immune disease research, and biomarker discovery.
• CS GeneticscoreTechnology or Integration · 14 October 2025Carolina Molecular was named one of the first Certified Service Providers for CS Genetics' SimpleCell platform, offering instrument-free scRNA-seq to US researchers. The partnership enables scalable, cost-efficient single-cell RNA sequencing across applications in neurobiology, developmental biology, cancer, and immunology.
• PhenoVista BiosciencescoreStrategic or Co-development Partner · 24 September 2025Partnership combining Carolina Molecular's molecular testing services with PhenoVista's high-content imaging and cell-based assay expertise. Clients gain access to combined phenotypic/functional cellular data and orthogonal molecular readouts including immunoassays, qPCR, and RNA sequencing to inform drug discovery.
• AstoriomcoreStrategic or Co-development Partner · 9 September 2025Carolina Molecular and Astoriom partnered to provide integrated molecular testing and biospecimen storage services for CROs, pharmaceutical, and biotechnology companies. The collaboration combines Carolina Molecular's CAP/CLIA-certified molecular testing capabilities with Astoriom's ICH-compliant stability storage and biorepository services spanning US, EU, and UK markets. Both Research Triangle Park, North Carolina-based companies aim to streamline workflows and reduce handling steps while maintaining sample integrity and regulatory compliance.
• Flagship BiosciencescoreStrategic or Co-development Partner · 20 August 2025Carolina Molecular performs all molecular testing services for Flagship Biosciences through its CLIA-certified, CAP-accredited laboratory. The partnership combines Flagship's spatial biology and histopathology expertise with Carolina Molecular's comprehensive molecular testing capabilities, creating a seamless tissue-to-data solution for pharma, biotech, and research institutions.
• IlluminacoreTechnology or IntegrationStrategic technology partner providing Illumina sequencing platforms (NovaSeq X Plus, NextSeq, MiSeq) for Carolina Molecular's sequencing services. Illumina platforms form the backbone of both clinical and RUO NGS workflows.
• Nanostring (GeoMx)coreTechnology or IntegrationTechnology partner providing GeoMx Digital Spatial Profiling platform for high-plex, spatially resolved RNA and protein profiling from tissue regions of interest. Integrated into Carolina Molecular's multiomic service offering.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Personalis: Personalis is a clinical genomics company offering tumor profiling, MRD detection, and immuno-oncology biomarker testing through its ImmunoID Next platform. It competes with Carolina Molecular's oncology and immuno-oncology molecular testing services.
• Caris Life Sciences: Caris provides molecular profiling services (DNA/RNA sequencing, whole exome, whole transcriptome) for oncology precision medicine, biopharma, and research customers. It competes directly with Carolina Molecular's clinical oncology and multiomic offerings.
• Tempus AI: Tempus AI is a technology-enabled precision medicine company providing NGS-based molecular profiling, multiomic analysis, and AI-driven bioinformatics to pharma and clinicians. It is a comparable next-generation molecular testing and analytics provider.
• Azenta Life Sciences (Genewiz): Azenta operates the Genewiz NGS services brand, offering Sanger, NGS, and synthetic biology services to pharma, biotech, and academic customers globally. It is the most direct large-scale competitor to Carolina Molecular's NGS Foundry and clinical sequencing services.
• PhenoVista Biosciences: PhenoVista is a strategic partner of Carolina Molecular providing high-content imaging and cell-based assay services. While a partner rather than competitor, its phenotypic assay capabilities overlap with Carolina Molecular's multiomic drug discovery workflow, making it a closely comparable specialty services lab.

Broad incumbents

• Quest Diagnostics: Quest Diagnostics is one of the largest US clinical laboratories offering a broad molecular diagnostics menu including infectious disease, oncology, and genetic testing. Its scale and payor relationships make it a dominant competitor in clinical molecular testing.
• Eurofins Genomics: Eurofins is a global leader in genomic services including Sanger sequencing, NGS, qPCR, and bioinformatics for pharma, food, and agricultural testing. It competes with Carolina Molecular across nearly every vertical the company serves, with much greater scale and geographic reach.
• NeoGenomics Laboratories: NeoGenomics is a CAP/CLIA-accredited clinical laboratory specializing in oncology molecular testing, including NGS panels, liquid biopsy, and hematologic cancer profiling. It is a meaningful incumbent competitor for Carolina Molecular's clinical oncology testing services.
• Labcorp (including BioReference): Labcorp is a major clinical and specialty testing laboratory providing molecular diagnostics, NGS, and clinical trial central lab services through its BioReference and Covance/Fortrea arms. It directly competes with Carolina Molecular in clinical trial molecular testing.

Others

• Element Biosciences: Element Biosciences manufactures the AVITI sequencing platform, which Carolina Molecular operates as a certified service provider. While not a direct competitor, Element is a critical ecosystem partner and adjacent supplier whose commercial strategy materially affects Carolina Molecular's service differentiation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/carolinamolecular

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Carolina Molecular